Of a total of 498 CTCs in metastatic patients [median of 3 CTCs/patient (range, 1–65) CTCs], 339 (68%) expressed IGF1R (Table 2) (Pα = 0.04 and Pβ = 0.002 compared to patients with early breast cancer). Here, IGF1R is linked to breast cancer.